AU738431B2 - Bioconjugates and delivery of bioactive agents - Google Patents

Bioconjugates and delivery of bioactive agents Download PDF

Info

Publication number
AU738431B2
AU738431B2 AU41482/97A AU4148297A AU738431B2 AU 738431 B2 AU738431 B2 AU 738431B2 AU 41482/97 A AU41482/97 A AU 41482/97A AU 4148297 A AU4148297 A AU 4148297A AU 738431 B2 AU738431 B2 AU 738431B2
Authority
AU
Australia
Prior art keywords
bioconjugate
bioactive agent
use according
cells
tissue site
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU41482/97A
Other languages
English (en)
Other versions
AU4148297A (en
Inventor
Charles B. Grissom
W. Allen Howard Jr.
Frederick G. West
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Utah Research Foundation Inc
Original Assignee
University of Utah Research Foundation Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Utah Research Foundation Inc filed Critical University of Utah Research Foundation Inc
Publication of AU4148297A publication Critical patent/AU4148297A/en
Application granted granted Critical
Publication of AU738431B2 publication Critical patent/AU738431B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
AU41482/97A 1996-08-27 1997-08-22 Bioconjugates and delivery of bioactive agents Ceased AU738431B2 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US2443096P 1996-08-27 1996-08-27
US2503696P 1996-08-27 1996-08-27
US60/025036 1996-08-27
US60/024430 1996-08-27
PCT/US1997/014140 WO1998008859A1 (en) 1996-08-27 1997-08-22 Bioconjugates and delivery of bioactive agents

Publications (2)

Publication Number Publication Date
AU4148297A AU4148297A (en) 1998-03-19
AU738431B2 true AU738431B2 (en) 2001-09-20

Family

ID=26698439

Family Applications (1)

Application Number Title Priority Date Filing Date
AU41482/97A Ceased AU738431B2 (en) 1996-08-27 1997-08-22 Bioconjugates and delivery of bioactive agents

Country Status (11)

Country Link
US (4) US6315978B1 (enExample)
EP (1) EP1007533B1 (enExample)
JP (1) JP2001501596A (enExample)
AT (1) ATE298344T1 (enExample)
AU (1) AU738431B2 (enExample)
CA (1) CA2264592C (enExample)
DE (1) DE69733618T2 (enExample)
ES (1) ES2244006T3 (enExample)
NZ (1) NZ334870A (enExample)
PT (1) PT1007533E (enExample)
WO (1) WO1998008859A1 (enExample)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5739313A (en) 1995-11-13 1998-04-14 Regents Of The University Of Minnesota Radionuclide labeling of vitamin B12 and coenzymes thereof
KR20020032421A (ko) * 1999-04-16 2002-05-03 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 항암제로서 유용한 코발라민 컨쥬게이트
US6806363B1 (en) 1999-04-16 2004-10-19 Mayo Foundation For Medical Education & Research Cobalamin conjugates useful as antitumor agents
WO2001028592A1 (en) * 1999-10-15 2001-04-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging agents and as antitumor agents
US7591995B2 (en) * 1999-10-15 2009-09-22 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
AU785505B2 (en) 1999-10-15 2009-02-26 Mayo Foundation For Medical Education And Research Cobalamin conjugates useful as imaging and therapeutic agents
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6797521B2 (en) * 1999-10-26 2004-09-28 University Of Utah Research Foundation Fluorescent cobalamins and uses thereof
DE10012120A1 (de) * 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
WO2001092288A2 (en) * 2000-05-31 2001-12-06 Mayo Foundation For Medical Education And Research Cobalamin compounds useful as antibiotic agents and as imaging agents
US20020049155A1 (en) * 2000-05-31 2002-04-25 Hogenkamp Henricus P.C. Cobalamin compounds useful as cardiovascular agents and as imaging agents
CN1292798C (zh) 2000-06-02 2007-01-03 德克萨斯州立大学董事会 乙二半胱氨酸(ec)－药物缀合物
EP1754712A3 (en) * 2000-10-25 2009-01-14 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
WO2002055530A2 (en) * 2000-10-25 2002-07-18 Mayo Foundation Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
AU2002239342A1 (en) * 2000-11-22 2002-06-03 Rxkinetix, Inc. Treatment of mucositis
WO2002076394A2 (en) * 2001-03-22 2002-10-03 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
US6752986B2 (en) * 2001-05-24 2004-06-22 The Cleveland Clinic Foundation Composition and methods for affecting metallocorrinoid uptake
US20030031627A1 (en) * 2001-07-31 2003-02-13 Mallinckrodt Inc. Internal image antibodies for optical imaging and therapy
WO2003026674A1 (en) * 2001-09-28 2003-04-03 Mayo Foundation For Medical Education And Research Coadministration of transport protein with conjugated cobalamin to deliver agents
US6679827B2 (en) 2001-10-11 2004-01-20 Robert E. Sandstrom Magnetic field enhancement of tumor treatment
US9657294B2 (en) 2002-02-20 2017-05-23 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US20040047917A1 (en) * 2002-09-06 2004-03-11 Stephen Wilson Drug delivery and targeting with vitamin B12 conjugates
US7627373B2 (en) 2002-11-30 2009-12-01 Cardiac Pacemakers, Inc. Method and apparatus for cell and electrical therapy of living tissue
EP1596815A4 (en) * 2003-02-20 2007-07-04 Cleveland Clinic Foundation COMPOSITION AND METHOD FOR INHIBITING THE SURVIVAL OF CELLS
US7232805B2 (en) * 2003-09-10 2007-06-19 Inflabloc Pharmaceuticals, Inc. Cobalamin conjugates for anti-tumor therapy
US7119065B2 (en) * 2003-10-29 2006-10-10 Nagoya Industrial Science Research Institute Metal complex-protein composite and oxidation catalyst
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
US7840263B2 (en) 2004-02-27 2010-11-23 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression
US7764995B2 (en) 2004-06-07 2010-07-27 Cardiac Pacemakers, Inc. Method and apparatus to modulate cellular regeneration post myocardial infarct
US7729761B2 (en) * 2004-07-14 2010-06-01 Cardiac Pacemakers, Inc. Method and apparatus for controlled gene or protein delivery
US8288557B2 (en) 2004-07-23 2012-10-16 Endocyte, Inc. Bivalent linkers and conjugates thereof
US8202507B2 (en) * 2004-09-23 2012-06-19 The Regents Of The University Of California Assay for vitamin B12 absorption and method of making labeled vitamin B12
US8060219B2 (en) 2004-12-20 2011-11-15 Cardiac Pacemakers, Inc. Epicardial patch including isolated extracellular matrix with pacing electrodes
US7981065B2 (en) 2004-12-20 2011-07-19 Cardiac Pacemakers, Inc. Lead electrode incorporating extracellular matrix
EP1893038A1 (en) * 2005-05-17 2008-03-05 Cargill, Incorporated Granular lecithins, granular lysolecithins, process for their production and compositions containing them
BRPI0615354A2 (pt) * 2005-08-19 2011-05-17 Endocyte Inc conjugado de liberação de fármaco de ligação de receptor, composição farmacêutica que o compreende, bem como seu uso
US7774057B2 (en) 2005-09-06 2010-08-10 Cardiac Pacemakers, Inc. Method and apparatus for device controlled gene expression for cardiac protection
CA2635603C (en) * 2005-11-30 2016-01-19 Endo Pharmaceuticals Inc. Treatment of xerostomia
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
WO2008101231A2 (en) 2007-02-16 2008-08-21 Endocyte, Inc. Methods and compositions for treating and diagnosing kidney disease
EP2131855A2 (en) 2007-03-05 2009-12-16 Syracuse University A conjugate of insulin and vitamin b12 for oral delivery
CN104127878A (zh) 2007-03-14 2014-11-05 恩多塞特公司 结合配体连接的微管溶素递药缀合物
US20080233135A1 (en) * 2007-03-19 2008-09-25 Gebhard John R Cobalamin taxane bioconjugates
BRPI0811248A2 (pt) 2007-05-16 2014-11-04 Ktb Tumorforschungs Gmbh Formulação de antraciclina de baixa viscosidade.
US9877965B2 (en) 2007-06-25 2018-01-30 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
CN104383553A (zh) 2007-06-25 2015-03-04 恩多塞特公司 含有亲水性间隔区接头的共轭物
US8529426B2 (en) 2007-10-18 2013-09-10 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US9557635B2 (en) * 2007-10-18 2017-01-31 Gearbox, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8684898B2 (en) * 2007-10-18 2014-04-01 The Invention Science Fund I Llc Ionizing-radiation-responsive compositions, methods, and systems
US8168958B2 (en) * 2007-10-18 2012-05-01 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US8164074B2 (en) * 2007-10-18 2012-04-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
GB2453860B (en) 2007-10-18 2011-03-16 Searete Llc Ionizing-radiation-responsive compositions,methods and systems
US8227204B2 (en) * 2007-10-18 2012-07-24 The Invention Science Fund I, Llc Ionizing-radiation-responsive compositions, methods, and systems
US20090104113A1 (en) * 2007-10-18 2009-04-23 Searete Llc Ionizing-radiation-responsive compositions, methods, and systems
US20090169484A1 (en) 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
JP2009274962A (ja) * 2008-05-12 2009-11-26 Yoshihiro Ishikawa 鉄サレン錯体、磁性を有する薬剤、薬剤の誘導システム、並びに磁気検出装置
US20100016256A1 (en) * 2008-07-21 2010-01-21 Gebhard John R Taxane Compounds for Treating Eye Disease
WO2010058280A1 (ja) * 2008-11-20 2010-05-27 株式会社Ihi 自己磁性金属サレン錯体化合物
CN102834512A (zh) * 2010-04-06 2012-12-19 株式会社Ihi 金属salen配合物衍生物及其制造方法
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
KR20140026396A (ko) 2011-03-08 2014-03-05 어섹스 팔마큐티칼스 인코포레이티드 생물학적 막을 가로질러 활성물질의 전달을 위한 표적화된 나노담체 시스템
WO2013126797A1 (en) 2012-02-24 2013-08-29 Purdue Research Foundation Cholecystokinin b receptor targeting for imaging and therapy
US20140080175A1 (en) 2012-03-29 2014-03-20 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
HK1212618A1 (zh) 2012-10-16 2016-06-17 恩多塞特公司 含有非天然氨基酸的藥物遞送綴合物以及其使用方法
US9352049B2 (en) 2013-03-14 2016-05-31 Albany Molecular Research, Inc. Ligand-therapeutic agent conjugates, silicon-based linkers, and methods for making and using them
JP2016516774A (ja) * 2013-04-08 2016-06-09 ユニバーシティー オブ ノースキャロライナ アット チャペル ヒルＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｃａｒｏｌｉｎａ Ａｔ Ｃｈａｐｅｌ Ｈｉｌｌ 光応答性化合物
RS57418B1 (sr) * 2013-05-22 2018-09-28 Alnylam Pharmaceuticals Inc Serpina1 irnk sastavi i postupci njihove primene
CA2922698C (en) * 2013-08-29 2023-01-03 City Of Hope Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids
GR20130100654A (el) * 2013-11-22 2015-06-18 Χρηστος Γκολφινου Ταπεινος Επιφανειακως τροποποιημενα πολλαπλως αποκρινομενα σε ερεθισματα νανο/μικρο-δοχεια ως φορεις φαρμακων για στοχευμενη θεραπεια διαφορων μορφων καρκινου
WO2020113130A1 (en) * 2018-11-29 2020-06-04 The Trustees Of Dartmouth College Tumor targeting vitamin b12 derivatives for x-ray activated chemotherapy
GB202018713D0 (en) 2020-11-27 2021-01-13 Quadram Inst Bioscience Methods and compositions utilising vitamin b12 binding

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4758421A (en) * 1985-03-15 1988-07-19 The Board Of Trustees Of The Leland Stanford Junior University Bleomycin conjugates and method
NZ217821A (en) * 1985-10-10 1989-07-27 Biotech Australia Pty Ltd Oral delivery system; complex of active agent and vitamin b12 or analogue thereof
EP0394277B1 (en) * 1987-07-15 1998-01-14 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Second generation monoclonal antibodies having binding specificity to tag-72 and human carcinomas and methods for employing the same
US5047227A (en) * 1988-02-08 1991-09-10 Cytogen Corporation Novel and improved antibodies for site specific attachment of compounds
WO1990012095A1 (en) * 1989-04-03 1990-10-18 Purdue Research Foundation Method for enhancing transmembrane transport of exogenous molecules
US5608046A (en) * 1990-07-27 1997-03-04 Isis Pharmaceuticals, Inc. Conjugated 4'-desmethyl nucleoside analog compounds
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
WO1994028015A1 (en) * 1993-05-20 1994-12-08 Biotech Australia Pty. Limited Lhrh antagonists
US5548064A (en) * 1993-05-24 1996-08-20 Biotech Australia Pty Limited Vitamin B12 conjugates with EPO, analogues thereof and pharmaceutical compositions
EP0754189B1 (en) * 1994-04-08 2002-10-09 Receptagen Corporation Receptor modulating agents and methods relating thereto
US5574018A (en) * 1994-07-29 1996-11-12 Amgen Inc. Conjugates of vitamin B12 and proteins

Also Published As

Publication number Publication date
NZ334870A (en) 2000-12-22
WO1998008859A1 (en) 1998-03-05
JP2001501596A (ja) 2001-02-06
DE69733618D1 (de) 2005-07-28
US20020111294A1 (en) 2002-08-15
US20020115595A1 (en) 2002-08-22
AU4148297A (en) 1998-03-19
DE69733618T2 (de) 2006-05-11
US20020049154A1 (en) 2002-04-25
US6776976B2 (en) 2004-08-17
CA2264592A1 (en) 1998-03-05
ES2244006T3 (es) 2005-12-01
US6790827B2 (en) 2004-09-14
EP1007533A4 (en) 2002-08-07
US6777237B2 (en) 2004-08-17
PT1007533E (pt) 2005-09-30
EP1007533A1 (en) 2000-06-14
EP1007533B1 (en) 2005-06-22
US6315978B1 (en) 2001-11-13
CA2264592C (en) 2012-02-21
ATE298344T1 (de) 2005-07-15

Similar Documents

Publication Publication Date Title
AU738431B2 (en) Bioconjugates and delivery of bioactive agents
Lee et al. Shining new light on biological systems: Luminescent transition metal complexes for bioimaging and biosensing applications
Kim et al. Biomedical applications of copper-free click chemistry: in vitro, in vivo, and ex vivo
Nkepang et al. Folate receptor-mediated enhanced and specific delivery of far-red light-activatable prodrugs of combretastatin A-4 to FR-positive tumor
Maruani et al. Site-selective multi-porphyrin attachment enables the formation of a next-generation antibody-based photodynamic therapeutic
Schneider et al. Design, synthesis, and biological evaluation of folic acid targeted tetraphenylporphyrin as novel photosensitizers for selective photodynamic therapy
Vlahov et al. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide
KR100365058B1 (ko) 텍사피린을사용하는방사선감작방법
JP3232347B2 (ja) 外因性分子の経膜的輸送を高める方法
JP6223962B2 (ja) トランス−シクロオクテンジエノフィル及びジエンを有するイメージング又は治療用プレターゲティングキット
WO2014081300A1 (en) Channel protein activatable liposomes
WO2014081299A1 (en) Activatable liposomes
JP2011518890A (ja) 新規のクロリンｅ６−葉酸結合化合物、その製造方法、およびそれを含有する癌治療用薬学的組成物
Zhao et al. Glutathione‐triggered prodrugs: Design strategies, potential applications, and perspectives
Lu et al. Membrane-tethered activation design of a photosensitizer boosts systemic antitumor immunity via pyroptosis
Ragab Signature of click chemistry in advanced techniques for cancer therapeutics
WO2007075680A2 (en) System and method for delivering a desired material to a cell
KR20190075389A (ko) 항암제가 담지된 나노구조체를 유효성분으로 포함하는 간암 치료용 약학조성물
Li Study on synthesis and biological activity of a galactosylated piperazinyl porphyrin
Akhter et al. Porphyrin-based nanomaterials for cancer nanotheranostics
KR100911250B1 (ko) 신규한 클로린 ｅ６-엽산 결합 화합물의 제조방법
Semakov et al. Low Molecular Weight Modifications of Anthracycline Antibiotics. Part II. Reactions by Other Positions (A Review)
Schiefer Towards accelerated bioorthogonal drug activation in cancer cells upon independent double-targeting
Welfare Exploration and Expansion of the Photolytic Properties of Cobalamin
EP1309330B1 (en) Photosensitizers with ligand targeting properties for tumor therapy

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)